Liabilities / Assets
Score unavailable
Liabilities-to-assets requires both liabilities and assets on the latest valid filing.
North Bay Neuroscience Institute
EIN 83-1580566 • 501(c)3 • Sebastopol, CA
Profile
Prior to being notified of the cessation of testing for potential Alzheimer drugs, our work involved researching different potential medicines that may impact the onset of Alzheimers Disease. We worked with pharmaceutical companies which are in various trial stages of developing these new drugs. Our job was to work with patient subjects who had early Alzheimer indications and wanted to try these trial drugs. Their participation in these studies helped us all understand ways to beat Alzheimers Disease.
Siviq Scores
Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.
No value available
Liabilities / Revenue
Score unavailable
Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.
Net Margin
5th percentile
Higher net margin than 5% of similar nonprofits.
Top Officer Pay
98th percentile
Higher top officer pay than 98% of similar nonprofits.
Top officer pay equals 155.1% of source-year revenue.
Asset Growth
10th percentile
Faster asset growth than 10% of similar nonprofits.
Revenue Growth
6th percentile
Faster revenue growth than 6% of similar nonprofits.
Balance Sheet
Assets
Down$0
Down $265,276 (-100%) from 2019
Liabilities
-
No earlier filing loaded for comparison.
Net Assets
Down$0
Down $252,729 (-100%) from 2019
Revenue
Down$60,222
Down $820,848 (-93%) from 2019
Expenses
Down$312,951
Down $373,104 (-54%) from 2019
Net Income
Down-$252,729
Down $447,744 (-230%) from 2019
Trend Graphs
Filings
Most recent year
2020 • Form 990EZDetailed filing. Detailed filing data is available for this year.
- Assets
- $0
- Liabilities
- -
- Net assets
- $0
- Revenue
- $60,222
- Expenses
- $312,951
- Net income
- -$252,729
| Balance Sheet | Operations | |||||
|---|---|---|---|---|---|---|
| Year | Assets | Liabilities | Net Assets | Revenue | Expenses | Net Income |
| 2020Detailed filing. Detailed filing data is available for this year. | $0.00 | $0.00 | $0.60 | $3.13 | $2.53 | |
| 2019Detailed filing. Detailed filing data is available for this year. | $2.65 | $0.13 | $2.53 | $8.81 | $6.86 | $1.95 |
| 2018Summary only. Only limited summary data is available for this year. | $0.72 | $0.15 | $0.58 | $3.14 | $2.56 | $0.58 |
Latest Filing Detail
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2020 to Dec 31, 2020
- Signed
- May 17, 2021
- Return Version
- 2020v4.0
- Gross Receipts
- $61,711
Mission and Program Overview
Mission
Prior to being notified of the cessation of testing for potential Alzheimer drugs, our work involved researching different potential medicines that may impact the onset of Alzheimers Disease. We worked with pharmaceutical companies which are in various trial stages of developing these new drugs. Our job was to work with patient subjects who had early Alzheimer indications and wanted to try these trial drugs. Their participation in these studies helped us all understand ways to beat Alzheimers Disease.
Program Services
| Description | Grants | Expenses |
|---|---|---|
| Biogen: Emerge Study - Evaluated the efficacy of the experimental drug aducanumab compared with a placebo in slowing cognitive and functional impairment in people with early-stage Alzheimer's disease. | - | - |
| Novartis: Generation 1 & 2 - Tested the safety and effects of the investgational drug CNP520 in cognitively normal older adults who are at risk of developing dementia based on their age, genetic status, and brain amyloid levels. | - | - |
| Eisai: Tested the efficacy of BAN2401 in participants with early Alzheimer's disease EAD by determining the superiority of BAN2401 compared with placebo on the chnage from baseline in the Clinical Dementia Rating-Sum of Boxes CDR-SB at 18 months of treatment in the Core Study. Also evaluates the log-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. | - | - |
Compensation and Service Providers
Employees
| Name | Title | Full / Part Time | Base | Other | Total |
|---|---|---|---|---|---|
| Terry Hess | Foundation Mgr. | FT | $93,417 | - | $93,417 |
| Maben Rainwater | Executive Director | FT | $52,500 | - | $52,500 |
| Beth Bollinger | Chairman | - | $0 | - | - |
| Soraya Saffarinia | Secretary | - | $0 | - | - |
Filing and Contact Details
Filer
- Filer Name
- North Bay Neuroscience Institute
- EIN
- 83-1580566
- Phone
- 7074771108
- Address
- 475 Vine Street, Sebastopol, CA 95472
Signing Officer
- Name
- Maben Rainwater
- Title
- Executive Director
- Signed
- 2021-05-17
- Discuss with paid preparer
- Yes
Preparer
- Firm
- DAS Financial Management Advisory Services LLC
- Address
- 2 Bridle Path Lane, Beverly Farms, MA 01915
- Preparer
- Derek A Smith
- Phone
- 5085231221
Supplemental Narrative
Additional Explanations
Other Expenses.1002
“Office Expenses $11677”
Other Expenses.1009
“Depreciation $224”
Other Expenses.1012
“Insurance $559”
Other Expenses.1
“Equipment Rental $5241”
Other Expenses.2
“Computer & Internet $778”
Other Expenses.3
“Payroll Processing Fees $476”
Other Expenses.4
“Business Licenses $95”
Other Assets.1003
“Machinery and Equipment - Beginning $1713 Machinery and Equipment - Ending $1489”
Other Assets.1004
“Miscellaneous - Beginning $0 Miscellaneous - Ending $-1489”
Other Assets.1005
“Accounts Receivable - Beginning $2676 Accounts Receivable - Ending $0”
Other Assets.1011
“Prepaid Expenses and Deferred Charges - Beginning $3500 Prepaid Expenses and Deferred Charges - Ending $0”
Total Liabilities.1001
“Accounts Payable and Accrued Expenses - Beginning $12336 Accounts Payable and Accrued Expenses - Ending $0”
Total Liabilities.1
“Payroll liabilities - Beginning $211 Payroll liabilities - Ending $0”
Activities Not Previously Reported to the IRS
“As a result of drug companies ending their testing arrangements with the Organization, the entity dissolved and pursuant to its charter contributed its remaining fund balances to another charity in Sebastopol, CA”
Raw XML Appendix173 raw XML fields
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990EZ/ActivitiesNotPreviouslyRptInd | 0 | true |
| IRS990EZ/AddressChangeInd | 0 | X |
| IRS990EZ/BooksInCareOfDetail/PersonNm | 0 | Maben Rainwater |
| IRS990EZ/BooksInCareOfDetail/PhoneNum | 0 | 7074771108 |
| IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 475 Vine Street |
| IRS990EZ/BooksInCareOfDetail/USAddress/CityNm | 0 | Sebastopol |
| IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | CA |
| IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 95472 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt | 0 | 257387 |
| IRS990EZ/ChgMadeToOrgnzngDocNotRptInd | 0 | false |
| IRS990EZ/CostOfGoodsSoldAmt | 0 | 0 |
| IRS990EZ/CostOrOtherBasisExpenseSaleAmt | 0 | 1489 |
| IRS990EZ/DonorAdvisedFndsInd | 0 | false |
| IRS990EZ/EngagedInExcessBenefitTransInd | 0 | false |
| IRS990EZ/ExcessOrDeficitForYearAmt | 0 | -252729 |
| IRS990EZ/FeesAndOtherPymtToIndCntrctAmt | 0 | 3000 |
| IRS990EZ/FiledScheduleAInd | 0 | true |
| IRS990EZ/FinalReturnInd | 0 | X |
| IRS990EZ/ForeignFinancialAccountInd | 0 | false |
| IRS990EZ/ForeignOfficeInd | 0 | false |
| IRS990EZ/Form1120PolFiledInd | 0 | false |
| IRS990EZ/Form990TotalAssetsGrp/BOYAmt | 0 | 265276 |
| IRS990EZ/Form990TotalAssetsGrp/EOYAmt | 0 | 0 |
| IRS990EZ/FundraisingGrossIncomeAmt | 0 | 0 |
| IRS990EZ/GainOrLossFromSaleOfAssetsAmt | 0 | -1489 |
| IRS990EZ/GrossReceiptsAmt | 0 | 61711 |
| IRS990EZ/InfoInScheduleOPartIIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIVInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartVIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartVInd | 0 | X |
| IRS990EZ/LobbyingActivitiesInd | 0 | false |
| IRS990EZ/MadeLoansToFromOfficersInd | 0 | false |
| IRS990EZ/MethodOfAccountingCashInd | 0 | X |
| IRS990EZ/NetAssetsOrFundBalancesBOYAmt | 0 | 252729 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt | 0 | 252729 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt | 0 | 0 |
| IRS990EZ/OccupancyRentUtltsAndMaintAmt | 0 | 73508 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 0 | 40.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 1 | 1.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 3 | 40.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 0 | 52500 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 3 | 93417 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 0 | Maben Rainwater |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 1 | Beth Bollinger |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 2 | Soraya Saffarinia |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 3 | Terry Hess |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 0 | Executive Dir. |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 1 | Chairman |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 2 | Secretary |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 3 | Foundation Mgr. |
| IRS990EZ/OperateHospitalInd | 0 | false |
| IRS990EZ/Organization501c3Ind | 0 | X |
| IRS990EZ/OrganizationDissolvedEtcInd | 0 | true |
| IRS990EZ/OrganizationHadUBIInd | 0 | false |
| IRS990EZ/OtherAssetsTotalDetail/BOYAmt | 0 | 7889 |
| IRS990EZ/OtherExpensesTotalAmt | 0 | 19050 |
| IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt | 0 | NONE |
| IRS990EZ/PartVIOfCompOfHghstPdEmplTxt | 0 | NONE |
| IRS990EZ/PoliticalCampaignActyInd | 0 | false |
| IRS990EZ/PrimaryExemptPurposeTxt | 0 | Prior to being notified of the cessation of testing for potential Alzheimer drugs, our work involved researching different potential medicines that may impact the onset of Alzheimers Disease. We worked with pharmaceutical companies which are in various trial stages of developing these new drugs. Our job was to work with patient subjects who had early Alzheimer indications and wanted to try these trial drugs. Their participation in these studies helped us all understand ways to beat Alzheimers Disease. |
| IRS990EZ/ProgramServiceRevenueAmt | 0 | 61711 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 0 | Biogen: Emerge Study - Evaluated the efficacy of the experimental drug aducanumab compared with a placebo in slowing cognitive and functional impairment in people with early-stage Alzheimer's disease. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 1 | Novartis: Generation 1 & 2 - Tested the safety and effects of the investgational drug CNP520 in cognitively normal older adults who are at risk of developing dementia based on their age, genetic status, and brain amyloid levels. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 2 | Eisai: Tested the efficacy of BAN2401 in participants with early Alzheimer's disease EAD by determining the superiority of BAN2401 compared with placebo on the chnage from baseline in the Clinical Dementia Rating-Sum of Boxes CDR-SB at 18 months of treatment in the Core Study. Also evaluates the log-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. |
| IRS990EZ/ProhibitedTaxShelterTransInd | 0 | false |
| IRS990EZ/RelatedOrganizationCtrlEntInd | 0 | false |
| IRS990EZ/SalariesOtherCompEmplBnftAmt | 0 | 217393 |
| IRS990EZ/ScheduleBNotRequiredInd | 0 | X |
| IRS990EZ/SchoolOperatingInd | 0 | false |
| IRS990EZ/SpecialEventsDirectExpensesAmt | 0 | 0 |
| IRS990EZ/StatesWhereCopyOfReturnIsFldCd | 0 | CA |
| IRS990EZ/SubjectToProxyTaxInd | 0 | false |
| IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt | 0 | 12547 |
| IRS990EZ/TanningServicesProvidedInd | 0 | false |
| IRS990EZ/TaxImposedOnOrganizationMgrAmt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4911Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4912Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4955Amt | 0 | 0 |
| IRS990EZ/TaxReimbursedByOrganizationAmt | 0 | 0 |
| IRS990EZ/TotalExpensesAmt | 0 | 312951 |
| IRS990EZ/TotalRevenueAmt | 0 | 60222 |
| IRS990EZ/TransactionWithControlEntInd | 0 | false |
| IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd | 0 | false |
| IRS990EZ/TypeOfOrganizationCorpInd | 0 | X |
| IRS990EZ/WebsiteAddressTxt | 0 | N/A |
| IRS990ScheduleA/HospitalNameAndAddressGrp/CityNm | 0 | Santa Rosa |
| IRS990ScheduleA/HospitalNameAndAddressGrp/StateAbbreviationCd | 0 | CA |
| IRS990ScheduleA/HospitalNameAndAddressGrp/SupportedOrganizationName/BusinessNameLine1Txt | 0 | Saint Josephs Hospital |
| IRS990ScheduleA/MedicalResearchOrganizationInd | 0 | X |
| IRS990ScheduleN/AssetsDistributedInd | 0 | true |
| IRS990ScheduleN/AttorneyGeneralNotifiedInd | 0 | false |
| IRS990ScheduleN/BondLiabilitiesDischargedInd | 0 | false |
| IRS990ScheduleN/BondsOutstandingInd | 0 | false |
| IRS990ScheduleN/DirectorOfSuccessorInd | 0 | false |
| IRS990ScheduleN/EmployeeOfSuccessorInd | 0 | false |
| IRS990ScheduleN/LiabilitiesPaidInd | 0 | true |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/AssetsDistriOrExpnssPaidDesc | 0 | Cash |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/DistributionDt | 0 | 2020-12-30 |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/EIN | 0 | 237043925 |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/FairMarketValueOfAssetAmt | 0 | 6727 |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/IRCSectionTxt | 0 | 501(c)(3) |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/MethodOfFMVDeterminationTxt | 0 | Cash Transfer |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/AddressLine1Txt | 0 | 167 N High Street |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/CityNm | 0 | Sebastopol |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/StateAbbreviationCd | 0 | CA |
| IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/ZIPCd | 0 | 95472 |
| IRS990ScheduleN/OwnerOfSuccessorInd | 0 | false |
| IRS990ScheduleN/ReceiveCompensationInd | 0 | false |
| IRS990ScheduleN/RequiredToNotifyAGInd | 0 | false |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 0 | Office Expenses $11677 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 1 | Depreciation $224 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 2 | Insurance $559 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 3 | Equipment Rental $5241 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 4 | Computer & Internet $778 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 5 | Payroll Processing Fees $476 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 6 | Business Licenses $95 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 7 | Machinery and Equipment - Beginning $1713 Machinery and Equipment - Ending $1489 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 8 | Miscellaneous - Beginning $0 Miscellaneous - Ending $-1489 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 9 | Accounts Receivable - Beginning $2676 Accounts Receivable - Ending $0 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 10 | Prepaid Expenses and Deferred Charges - Beginning $3500 Prepaid Expenses and Deferred Charges - Ending $0 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 11 | Accounts Payable and Accrued Expenses - Beginning $12336 Accounts Payable and Accrued Expenses - Ending $0 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 12 | Payroll liabilities - Beginning $211 Payroll liabilities - Ending $0 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 13 | As a result of drug companies ending their testing arrangements with the Organization, the entity dissolved and pursuant to its charter contributed its remaining fund balances to another charity in Sebastopol, CA |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | Other Expenses.1002 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 1 | Other Expenses.1009 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 2 | Other Expenses.1012 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 3 | Other Expenses.1 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 4 | Other Expenses.2 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 5 | Other Expenses.3 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 6 | Other Expenses.4 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 7 | Other Assets.1003 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 8 | Other Assets.1004 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 9 | Other Assets.1005 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 10 | Other Assets.1011 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 11 | Total Liabilities.1001 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 12 | Total Liabilities.1 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 13 | Activities Not Previously Reported to the IRS |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/AuthenticationAssuranceLevelCd | 0 | AAL1 |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/FederatedAssuranceLevelCd | 0 | FAL1 |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/IdentityAssuranceLevelCd | 0 | IAL1 |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/TrustedCustomerCd | 0 | 2 |
| ReturnHeader/BuildTS | 0 | 2022-09-23 18:48:47Z |
| ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd | 0 | true |
| ReturnHeader/BusinessOfficerGrp/PersonNm | 0 | Maben Rainwater |
| ReturnHeader/BusinessOfficerGrp/PersonTitleTxt | 0 | Executive Director |
| ReturnHeader/BusinessOfficerGrp/SignatureDt | 0 | 2021-05-17 |
| ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt | 0 | North Bay Neuroscience Institute |
| ReturnHeader/Filer/BusinessNameControlTxt | 0 | NORT |
| ReturnHeader/Filer/EIN | 0 | 831580566 |
| ReturnHeader/Filer/PhoneNum | 0 | 7074771108 |
| ReturnHeader/Filer/USAddress/AddressLine1Txt | 0 | 475 Vine Street |
| ReturnHeader/Filer/USAddress/CityNm | 0 | Sebastopol |
| ReturnHeader/Filer/USAddress/StateAbbreviationCd | 0 | CA |
| ReturnHeader/Filer/USAddress/ZIPCd | 0 | 95472 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt | 0 | DAS Financial Management Advisory Services LLC |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt | 0 | 2 Bridle Path Lane |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm | 0 | Beverly Farms |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd | 0 | MA |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd | 0 | 01915 |
| ReturnHeader/PreparerPersonGrp/PhoneNum | 0 | 5085231221 |
| ReturnHeader/PreparerPersonGrp/PreparerPersonNm | 0 | Derek A Smith |
| ReturnHeader/PreparerPersonGrp/SelfEmployedInd | 0 | X |
| ReturnHeader/ReturnTs | 0 | 2021-05-17T07:30:49-07:00 |
| ReturnHeader/ReturnTypeCd | 0 | 990EZ |
| ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm | 0 | Maben |
| ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm | 0 | Rainwater |
| ReturnHeader/TaxPeriodBeginDt | 0 | 2020-01-01 |
| ReturnHeader/TaxPeriodEndDt | 0 | 2020-12-31 |
| ReturnHeader/TaxYr | 0 | 2020 |
Document Assets
No mirrored PDF or thumbnail assets are attached yet.